Unilever is pouring €35 million into its Mumbai and Bengaluru R&D centres to boost AI and biotech innovation. While the move aims to sharpen product development, investors remain cautious as Hindustan Unilever shares have dropped nearly 20% this year amid margin pressure and weakening consumer demand.
Unilever is stepping up its research efforts in India with a fresh €35 million investment aimed at upgrading its facilities in Mumbai and Bengaluru. The funding is set to transform the company's local research hubs into a next-generation ecosystem that leverages artificial intelligence (AI) and biotechnology to accelerate product development.
The initiative focuses on two main areas. The Mumbai facility will be converted into a dedicated Product Innovation Centre, concentrating on AI-driven consumer insights, rapid prototyping, and advanced packaging design. Meanwhile, the Bengaluru hub will continue to serve as a global science and technology node, with a specific focus on foundational research and food technology. As part of this push, the company has committed €5 million over the next five years to a new "Bio-Futures" platform. This project is intended to bridge the gap between Unilever’s global research pipeline and India’s domestic bioscience ecosystem, with applications in areas like microbiome science and biomanufacturing.
Financial Context And Market Reaction
For shareholders of Hindustan Unilever (HUL), this investment signals a long-term commitment to product differentiation. However, the market sentiment has remained subdued. In its recent quarterly performance for the second quarter of the 2027 fiscal year, HUL reported a turnover of ₹18,071 crore, marking a 15% year-on-year increase. Despite the top-line growth, profitability has been under pressure. The company’s EBITDA margins contracted by 140 basis points to 22.6%, largely driven by persistent input cost inflation.
This margin compression is one of the factors weighing on the stock. HUL shares have faced significant selling pressure throughout 2026, declining by nearly 20% year-to-date. Investors are currently weighing the company’s solid balance sheet—it remains net-debt free with a healthy return on equity of 21-24%—against the difficult macroeconomic environment. The fast-moving consumer goods (FMCG) sector in India is currently battling a combination of high raw material prices and sluggish consumer demand, which has made investors more selective.
While the R&D-led innovation strategy is designed to help the company gain a competitive edge, the immediate benefit remains to be seen. The core monitorable for investors in the coming quarters will be the company's ability to navigate these sectoral headwinds and restore margin health. Whether this new technology-driven approach can effectively offset current inflationary pressures and boost volumes will be key to understanding the stock's future trajectory.